Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Monika K. Prelowska"'
Autor:
Dawid Mehlich, Michał Łomiak, Aleksandra Sobiborowicz, Alicja Mazan, Dagmara Dymerska, Łukasz M. Szewczyk, Anna Mehlich, Agnieszka Borowiec, Monika K. Prełowska, Adam Gorczyński, Paweł Jabłoński, Ewa Iżycka-Świeszewska, Dominika Nowis, Anna A. Marusiak
Publikováno v:
Cell Death and Disease, Vol 12, Iss 12, Pp 1-13 (2021)
Abstract Chemoresistance constitutes a major challenge in the treatment of triple-negative breast cancer (TNBC). Mixed-Lineage Kinase 4 (MLK4) is frequently amplified or overexpressed in TNBC where it facilitates the aggressive growth and migratory p
Externí odkaz:
https://doaj.org/article/a6cbcdae3c1744a89c3691e28b0246d5
Autor:
Aleksandra Sobiborowicz, Dominika Nowis, Paweł Jabłoński, Agnieszka Borowiec, Anna A Marusiak, Alicja Mazan, Monika K. Prelowska, Dawid Mehlich, Adam Gorczyński, Ewa Iżycka-Świeszewska, Michał Łomiak, Łukasz M. Szewczyk, Dagmara Dymerska, Anna Mehlich
Publikováno v:
Cell Death and Disease, Vol 12, Iss 12, Pp 1-13 (2021)
Cell Death & Disease
Cell Death & Disease
Chemoresistance constitutes a major challenge in the treatment of triple-negative breast cancer (TNBC). Mixed-Lineage Kinase 4 (MLK4) is frequently amplified or overexpressed in TNBC where it facilitates the aggressive growth and migratory potential
Autor:
Dawid Mehlich, Michal Lomiak, Aleksandra Sobiborowicz, Alicja Mazan, Dagmara Dymerska, Lukasz M. Szewczyk, Anna Mehlich, Agnieszka Borowiec, Monika K. Prelowska, Dominika Nowis, Anna A. Marusiak
Publikováno v:
Cancer Research. 82:151-151
Resistance to chemotherapy leads to high rates of relapse and poor outcomes in patients with triple-negative breast cancer (TNBC). Therefore, there is a need to identify novel molecular targets that could be exploited to overcome TNBC chemoresistance
Autor:
Hanna Kędzierska, Artur Kosnik, M. Talha Ugurlu, Dominika Nowis, Dawid Mehlich, Anna A. Marusiak, Klaudia Kaminska, Aleksandra Cwiek, Monika K. Prelowska
Publikováno v:
Cancer letters. 507
Proteasome inhibitors (PIs), used in the treatment of plasma cell myeloma (PCM), interfere with the degradation of misfolded proteins leading to activation of unfolded protein response (UPR) and cell death. However, despite initial strong antimyeloma
Autor:
Monika K. Prelowska, Dawid Mehlich, M. Talha Ugurlu, Hanna Kedzierska, Aleksandra Cwiek, Artur Kosnik, Klaudia Kaminska, Anna A. Marusiak, Dominika Nowis
Publikováno v:
Cancer Letters. 526:363
Autor:
Klaudia Kaminska, Hanna Kędzierska, Adam Gorczyński, Dawid Mehlich, Dominika Nowis, Wojciech Biernat, Dariusz Plewczynski, John Brognard, Michal Lazniewski, Aleksandra Korwat, Jakub Golab, Olga Sokolowska, Anna A. Marusiak, Monika K. Prelowska
Publikováno v:
Oncogene
Metastasis to distant organs is a major cause for solid cancer mortality, and the acquisition of migratory and invasive phenotype is a key factor in initiation of malignancy. In this study we investigated the contribution of Mixed-Lineage Kinase 4 (M